Proguanil氯胍,500-92-5

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Proguanil

CAS No. : 500-92-5

MCE 国际站：Proguanil

产品活性：Proguanil 是一种抗疟前药，被代谢为活性代谢物环鸟苷 (HY-12784)。Proguanil 是一种二氢叶酸还原酶 (DHFR) 抑制剂。

研究领域：Anti-infection | Cell Cycle/DNA Damage

作用靶点：Parasite | Antifolate

In Vitro: Proguanil per se has only weak antimalarial activity in vitro (IC₅₀=2.4-19 μM), and its effectiveness depends on the active metabolite Cycloguanil (IC₅₀=0.5-2.5 nM). The Cycloguanil is a dihydrofolate reductase (DHFR) inhibitor. The combination of Atovaquone and Proguanil is synergistic in vitro. Both drugs also have activity against gametocytes and pre-erythrocytic (hepatic) stages of malaria parasites.
Proguanil acts as a biguanide rather than as its metabolite Cycloguanil (a parasite dihydrofolate reductase [DHFR] inhibitor) to enhance the Atovaquone effect. Proguanil-mediated enhancement is specific for Atovaquone, since the effects of other mitochondrial electron transport inhibitors, such as Myxothiazole and Antimycin, are not altered by inclusion of Proguanil.
5-HT₃ receptor responses are reversibly inhibited by Proguanil, the metabolite 4-chlorophenyl-1-biguanide (CPB) and the active metabolite Cycloguanil (CG), with an IC₅₀ of 1.81, 1.48 and 4.36 μM, respectively.

In Vivo: Proguanil (p.o.; 2.9 mg/kg body weight; daily for 5 days and 6 weeks respectively) shows mild degenerative changes for five days, while shows severe degenerative changes for six weeks in wistar strain albino rats.
Serum testosterone level is significantly decreased for proguanil treatment rats.
Administration of Malarone (atovaquone and proguanil) to experimentally B. gibsoni infected two dogs in chronic stage and three dogs in acute stage results in decrease in parasitemia, and clinical improvements are observed.

相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Cell Cycle/DNA Damage Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Antiparasitic Compound library | Anti-Cancer Metabolism Compound Library | Children’s Drug Library | Chloroquine | Methotrexate | Hydroxychloroquine sulfate | Kaempferol | Metronidazole | Dihydroartemisinin | Pemetrexed | Ivermectin | Niclosamide | Artesunate | Eflornithine hydrochloride hydrate | Suramin sodium salt | Artemisinin | Halofuginone | Quinidine | Folinic acid calcium | Miransertib | Trimethoprim | RRx-001 | Doxycycline | Nitazoxanide | Atovaquone | Obatoclax Mesylate | Quinacrine dihydrochloride | Diminazene aceturate | Flufenamic acid

热门产品线：重组蛋白 | 化合物库 | 天然产物 | 染料试剂 | PROTAC | 同位素标记物 | 寡核苷酸

Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds | Oligonucleotides

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。